The safety of long-acting &szlig;2-agonists in the treatment of stable chronic obstructive pulmonary disease | Zendy

M. Decramer | Zendy; Hanania | Zendy; Jan Lötvall | Zendy; Barbara P. Yawn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease

Author(s) -

M. Decramer,

Hanania,

Jan Lötvall,

Barbara P. Yawn

Publication year - 2013

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s39018

Subject(s) - indacaterol , medicine , formoterol , copd , salmeterol , tolerability , adverse effect , placebo , exacerbation , bronchodilator , anesthesia , intensive care medicine , asthma , budesonide , alternative medicine , pathology

Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research